Literature DB >> 32524182

Neurofibromatosis 1-associated optic pathway gliomas.

Ben Shofty1, Liat Ben Sira2, Shlomi Constantini3.   

Abstract

BACKGROUND: Optic Pathway Gliomas (OPG) are the most common brain tumor in Neurofibromatosis 1 patients (NF1). They are found along the optic pathway and may involve the optic nerves, chiasm, retro-chiasmatic structures, and the optic radiations. NF1 associate OPG (NF1-OPG) have variable presentation, disease course and response to treatment. The optimal management is patient-specific and should be tailored by a multidisciplinary team. Age, sex, histology, and molecular markers may be important factors in the individualized decision-making process. Chemotherapy is the first-line treatment in cases of progressive tumors, and visual preservation is the main goal of treatment.
PURPOSE: In this paper we will review the disease, practical management, and recent advances of NF1-OPG.

Entities:  

Keywords:  Chemotherapy; Low-grade glioma; NF1; Neurofibromatosis 1; Neurosurgery; OPG; Optic pathway glioma; Radiotherapy

Mesh:

Year:  2020        PMID: 32524182     DOI: 10.1007/s00381-020-04697-1

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  58 in total

1.  A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.

Authors:  Saba Sharif; Meena Upadhyaya; Rosalie Ferner; Elisa Majounie; Andrew Shenton; Michael Baser; Nalin Thakker; D Gareth Evans
Journal:  J Med Genet       Date:  2011-01-28       Impact factor: 6.318

2.  Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.

Authors:  Michael J Fisher; Michael Loguidice; David H Gutmann; Robert Listernick; Rosalie E Ferner; Nicole J Ullrich; Roger J Packer; Uri Tabori; Robert O Hoffman; Simone L Ardern-Holmes; Trent R Hummel; Darren R Hargrave; Eric Bouffet; Joel Charrow; Larissa T Bilaniuk; Laura J Balcer; Lucy D'Agostino McGowan; Grant T Liu
Journal:  Ann Neurol       Date:  2014-05-14       Impact factor: 10.422

3.  Optic pathway gliomas in adults.

Authors:  Ben Shofty; Shlomi Constantini; Felix Bokstein; Zvi Ram; Liat Ben-Sira; Sigal Freedman; Gilad Vainer; Anat Kesler
Journal:  Neurosurgery       Date:  2014-03       Impact factor: 4.654

4.  Macrocephaly in neurofibromatosis type 1: a sign post for optic pathway gliomas?

Authors:  Christina Schindera; Kevin Wingeier; Barbara Goeggel Simonetti; Miriam Diepold; Claude B Nauer; Johannes Fleischhauer; Maja Steinlin
Journal:  Childs Nerv Syst       Date:  2011-08-07       Impact factor: 1.475

5.  No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.

Authors:  Sonja Hutter; Rosario M Piro; Sebastian M Waszak; Hildegard Kehrer-Sawatzki; Reinhard E Friedrich; Alvaro Lassaletta; Olaf Witt; Jan O Korbel; Peter Lichter; Martin U Schuhmann; Stefan M Pfister; Uri Tabori; Victor F Mautner; David T W Jones
Journal:  Hum Genet       Date:  2016-03-11       Impact factor: 4.132

6.  Natural history and outcome of optic pathway gliomas in children.

Authors:  Gary Nicolin; Patricia Parkin; Donald Mabbott; Darren Hargrave; Ute Bartels; Uri Tabori; James Rutka; J Raymond Buncic; Eric Bouffet
Journal:  Pediatr Blood Cancer       Date:  2009-12-15       Impact factor: 3.167

7.  Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.

Authors:  Gaelle Blanchard; Marie-Pierre Lafforgue; Laurence Lion-François; Isabelle Kemlin; Diana Rodriguez; Pierre Castelnau; Maryline Carneiro; Pierre Meyer; François Rivier; Sébastien Barbarot; Yves Chaix
Journal:  Eur J Paediatr Neurol       Date:  2015-12-17       Impact factor: 3.140

Review 8.  Neurofibromatosis.

Authors:  Andrea I McClatchey
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

9.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

10.  Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1.

Authors:  M A Blazo; R A Lewis; M M Chintagumpala; M Frazier; C McCluggage; S E Plon
Journal:  Am J Med Genet A       Date:  2004-06-15       Impact factor: 2.802

View more
  5 in total

1.  Monomodality versus Combined Therapy in Optic Pathway Gliomas-20-Year Experience from a Singapore Children's Hospital.

Authors:  Jia Xu Lim; Enrica E K Tan; Lee Ping Ng; Wan Tew Seow; Kenneth T E Chang; Ru Xin Wong; Wen Shen Looi; David C Y Low; Sharon Y Y Low
Journal:  Front Surg       Date:  2022-05-02

2.  Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1.

Authors:  Laura-Nanna Lohkamp; Patricia Parkin; Allan Puran; Ute Katharina Bartels; Eric Bouffet; Uri Tabori; James Thomas Rutka
Journal:  Front Surg       Date:  2022-05-03

Review 3.  Neurosurgery for Optic Pathway Glioma: Optimizing Multidisciplinary Management.

Authors:  Derek C Samples; Jean M Mulcahy Levy; Todd C Hankinson
Journal:  Front Surg       Date:  2022-05-04

4.  A 40-Year Cohort Study of Evolving Hypothalamic Dysfunction in Infants and Young Children (<3 years) with Optic Pathway Gliomas.

Authors:  Stefania Picariello; Manuela Cerbone; Felice D'Arco; Hoong-Wei Gan; Patricia O'Hare; Kristian Aquilina; Enrico Opocher; Darren Hargrave; Helen A Spoudeas
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

Review 5.  Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.

Authors:  Robert Galvin; Adrienne L Watson; David A Largaespada; Nancy Ratner; Sara Osum; Christopher L Moertel
Journal:  Curr Oncol Rep       Date:  2021-03-15       Impact factor: 5.075

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.